285 related articles for article (PubMed ID: 34633639)
1. Clinical and Economic Burden of Pneumococcal Disease Due to Serotypes Contained in Current and Investigational Pneumococcal Conjugate Vaccines in Children Under Five Years of Age.
Wasserman MD; Perdrizet J; Grant L; Hayford K; Singh S; Saharia P; Horn EK; Farkouh RA
Infect Dis Ther; 2021 Dec; 10(4):2701-2720. PubMed ID: 34633639
[TBL] [Abstract][Full Text] [Related]
2. Reanalysis of the Clinical and Economic Burden of Pneumococcal Disease Due to Serotypes Contained in Current and Investigational Pneumococcal Conjugate Vaccines in Children < 5 Age: A Societal Perspective.
Li X; Warren S; Rozenbaum MH; Perdrizet J
Infect Dis Ther; 2023 Mar; 12(3):997-1006. PubMed ID: 36867396
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness of PCV20 to Prevent Pneumococcal Disease in the Pediatric Population: A German Societal Perspective Analysis.
Ta A; Kühne F; Laurenz M; von Eiff C; Warren S; Perdrizet J
Infect Dis Ther; 2024 Jun; 13(6):1333-1358. PubMed ID: 38733494
[TBL] [Abstract][Full Text] [Related]
4. Burden of pneumococcal disease due to serotypes covered by the 13-valent and new higher-valent pneumococcal conjugate vaccines in the United States.
Huang L; Wasserman M; Grant L; Farkouh R; Snow V; Arguedas A; Chilson E; Sato R; Perdrizet J
Vaccine; 2022 Aug; 40(33):4700-4708. PubMed ID: 35753839
[TBL] [Abstract][Full Text] [Related]
5. Cost-Effectiveness Analysis of the South African Infant National Immunization Program for the Prevention of Pneumococcal Disease.
Huang L; McDade CL; Perdrizet JE; Wilson MR; Warren SA; Nzenze S; Sewdas R
Infect Dis Ther; 2023 Mar; 12(3):933-950. PubMed ID: 36774428
[TBL] [Abstract][Full Text] [Related]
6. Assessing Public Health Impact of Four Pediatric Pneumococcal Conjugate Vaccination Strategies in the Netherlands.
Wilson M; McDade C; Beby-Heijtel AT; Waterval-Overbeek A; Sundaram V; Perdrizet J
Infect Dis Ther; 2023 Jul; 12(7):1809-1821. PubMed ID: 37318710
[TBL] [Abstract][Full Text] [Related]
7. Distribution of Serotypes Causing Invasive Pneumococcal Disease in Children From High-Income Countries and the Impact of Pediatric Pneumococcal Vaccination.
Grant LR; Slack MPE; Theilacker C; Vojicic J; Dion S; Reinert RR; Jodar L; Gessner BD
Clin Infect Dis; 2023 Feb; 76(3):e1062-e1070. PubMed ID: 35789262
[TBL] [Abstract][Full Text] [Related]
8. Cost-Effectiveness of 20-Valent Pneumococcal Conjugate Vaccine in Argentinean Adults.
Rey-Ares L; Averin A; Mac Mullen M; Hariharan D; Atwood M; Carballo C; Huang L
Infect Dis Ther; 2024 Jun; 13(6):1235-1251. PubMed ID: 38700655
[TBL] [Abstract][Full Text] [Related]
9. Distribution of serotypes causing invasive pneumococcal disease in older adults from high-income countries and impact of pediatric and adult vaccination policies.
Grant LR; Slack MPE; Theilacker C; Vojicic J; Dion S; Reinert RR; Jodar L; Gessner BD
Vaccine; 2023 Aug; 41(38):5662-5669. PubMed ID: 37544825
[TBL] [Abstract][Full Text] [Related]
10. Invasive pneumococcal disease in Canada 2010-2017: The role of current and next-generation higher-valent pneumococcal conjugate vaccines.
Dion SB; Major M; Gabriela Grajales A; Nepal RM; Cane A; Gessner B; Vojicic J; Suaya JA
Vaccine; 2021 May; 39(22):3007-3017. PubMed ID: 33824041
[TBL] [Abstract][Full Text] [Related]
11. Invasive pneumococcal disease among the elderly in the later era of paediatric pneumococcal conjugate vaccination-A longitudinal study over 10 years based on public surveillance data in the Nordics.
Palmborg A; Skovdal M; Molden T; Åhman H; Chen L; Banefelt J
PLoS One; 2023; 18(6):e0287378. PubMed ID: 37363884
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness of a 10- versus 13-valent pneumococcal conjugate vaccine in Denmark and Sweden.
Klok RM; Lindkvist RM; Ekelund M; Farkouh RA; Strutton DR
Clin Ther; 2013 Feb; 35(2):119-34. PubMed ID: 23312274
[TBL] [Abstract][Full Text] [Related]
13. Historical Population-Level Impact of Infant 13-Valent Pneumococcal Conjugate Vaccine (PCV13) National Immunization Programs on Invasive Pneumococcal Disease in Australia, Canada, England and Wales, Israel, and the United States.
Perdrizet J; Horn EK; Hayford K; Grant L; Barry R; Huang L; McDade C; Wilson M
Infect Dis Ther; 2023 May; 12(5):1351-1364. PubMed ID: 37079175
[TBL] [Abstract][Full Text] [Related]
14. Mathematical modeling of pneumococcal transmission dynamics in response to PCV13 infant vaccination in Germany predicts increasing IPD burden due to serotypes included in next-generation PCVs.
Horn M; Theilacker C; Sprenger R; von Eiff C; Mahar E; Schiffner-Rohe J; Pletz MW; van der Linden M; Scholz M
PLoS One; 2023; 18(2):e0281261. PubMed ID: 36791091
[TBL] [Abstract][Full Text] [Related]
15. Health and economic burden of invasive pneumococcal disease associated with 15-valent pneumococcal conjugate vaccine serotypes in children across eight European countries.
Hu T; Weiss T; Bencina G; Owusu-Edusei K; Petigara T
J Med Econ; 2021; 24(1):1098-1107. PubMed ID: 34461796
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness analysis of the pediatric 20-valent pneumococcal conjugate vaccine compared with lower-valent alternatives in Argentina.
Rey-Ares L; Ta A; Freigofaite D; Warren S; Mac Mullen M; Carballo C; Huang L
Vaccine; 2024 Jun; ():. PubMed ID: 38879409
[TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness of 2 + 1 dosing of 13-valent and 10-valent pneumococcal conjugate vaccines in Canada.
Earnshaw SR; McDade CL; Zanotti G; Farkouh RA; Strutton D
BMC Infect Dis; 2012 Apr; 12():101. PubMed ID: 22530841
[TBL] [Abstract][Full Text] [Related]
18. Estimating the Clinical and Economic Impact of Switching from the 13-Valent Pneumococcal Conjugate Vaccine (PCV13) to Higher-Valent Options in Greek Infants.
Warren S; Barmpouni M; Kossyvaki V; Gourzoulidis G; Perdrizet J
Vaccines (Basel); 2023 Aug; 11(8):. PubMed ID: 37631937
[TBL] [Abstract][Full Text] [Related]
19. Clinical and Economic Impact of a Potential Switch from 13-Valent to 10-Valent Pneumococcal Conjugate Infant Vaccination in Canada.
Wilson M; Wasserman M; Jadavi T; Postma M; Breton MC; Peloquin F; Earnshaw S; McDade C; Sings H; Farkouh R
Infect Dis Ther; 2018 Sep; 7(3):353-371. PubMed ID: 29934878
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness of a national immunization program with the 13-valent pneumococcal conjugate vaccine compared with the 10-valent pneumococcal conjugate vaccine in South Korea.
Kim HY; Park SB; Kang ES; Lee SM; Kim HJ; Wasserman M
Hum Vaccin Immunother; 2021 Mar; 17(3):909-918. PubMed ID: 32783576
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
